Hirotake Mizutani

Hirotake Mizutani

Auto-generated profile, based on publicly available information

Hirotake Mizutani

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2001 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
CLCourtney A. Luchaco-Cullis
Courtney A. Luchaco-Cullis
HMHirotake Mizutani
Hirotake Mizutani
KMKerry E. Murphy
Kerry E. Murphy
AHAmir H. Hoveyda
Amir H. Hoveyda

21 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SXStanley C. Xie
Stanley C. Xie
RMRiley D. Metcalfe
Riley D. Metcalfe
HMHirotake Mizutani
Hirotake Mizutani
TPTanya Puhalovich
Tanya Puhalovich
EHEric Hanssen
Eric Hanssen
LTLeann Tilley
Leann Tilley
Significance: Here, we describe inhibitors of the Plasmodium proteasome, an enzymatic complex that malaria parasites rely on to degrade proteins. Starting from inhibitors developed to treat cancer, derivatives were designed and synthesized with the aim of increasing potency against the Plasmodium proteasome and decreasing activity against the human enzyme. Biochemical and cellular assays identified compounds that exhibit selectivity and potency, both in vitro and in vivo, at different stages of the parasite’s lifecycle. Cryo-electron microscopy revealed that the inhibitors bind in a hydrophobic pocket that is structurally different in the human proteasome—underpinning their selectivity. The work will help develop antimalarial therapeutics, which are desperately needed to treat a disease that kills nearly half a million people annually.


16 July 2002 in ChemInform
Verified
Journal Article
Closed access
PDF file
HMHirotake Mizutani
Hirotake Mizutani
SDSylvia J. Degrado
Sylvia J. Degrado
AHAmir H. Hoveyda
Amir H. Hoveyda